Squire Patton Boggs is pleased to announce the addition of David A. Manspeizer and Greg Chopskie as partners of the firm’s Intellectual Property & Technology (IP&T) Practice based in New York and San Francisco, respectively. They arrive from Morrison & Foerster.
“David and Greg add unique skillsets and experience to our best-in-class life and health sciences IP practice,” said David Elkins, Squire Patton Boggs global IP&T Practice chair. “We already had strong patent and litigation practices in this area, but David and Greg bridge the two. Among other things, the pair has spent many years helping innovator life sciences companies anticipate and plan for attempted challenges to high-value drug patent portfolios by generic pharmaceutical companies. Lawyers with the expertise David and Greg have are few and far between. Having them immediately helps our global IP&T team deliver greater value to our clients.”
Mr. Manspeizer represents industry-leading global pharmaceutical and biotechnology companies in complex patent matters, including litigation, infringement, counseling and due diligence, as well as providing strategic portfolio advice. He spent part of his career as Vice President – Intellectual Property and Associate General Counsel at Wyeth, a pharmaceutical and biotechnology company (acquired by Pfizer), where he was responsible for all the company’s patent, trademark, copyright and trade secret matters. Mr. Manspeizer also has experience advising clients on the IP aspects of licensing and other transactional matters, including settlements.
By incorporating his extensive background as in-house counsel to several multibillion-dollar publicly traded life sciences companies, Mr. Chopskie focuses on developing effective legal strategies and tactics in both domestic and international IP disputes, with a niche capability in Hatch-Waxman litigation. His in-house career includes positions at Wyeth, Shionogi Inc. Pfizer and Gilead Sciences, Inc., where he specialized in creating groundbreaking IP, regulatory, litigation and commercial strategies to address generic competitors, in addition to creating a rigorous patent portfolio review program. His proficiency also includes IP portfolio design, due diligence, and international commercial transactions and competition matters.
“We were attracted to the Squire Patton Boggs IP&T Practice’s stellar reputation, particularly for its work in the life science/health patent space,” said Mr. Manspeizer. “We look forward to collaborating with our new colleagues and contributing to the growth of this already best-in-class team.”
“The firm’s international platform, proven industry track-record and collaborative culture made this firm an ideal match for us and for our clients. The opportunities we have here are unrivaled, and we are excited to hit the ground running,” added Mr. Chopskie.
In the past year, Squire Patton Boggs has made a number of significant additions to its IP&T Practice, with partners Frank L. Bernstein, Vid R. Bhakar and Ronald S. Lemieux joining the firm in Palo Alto from IP boutique Singularity LLP, and life sciences partner Todd Lorenz joining in San Francisco from Arnold & Porter Kaye Scholer.